Blood Glucose in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation

Launched by UNIVERSITY OF AARHUS · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the medication betamethasone, which is used to help develop the lungs of a baby when a mother is at risk of giving birth early, affects blood sugar levels in pregnant women who do not have diabetes. While it's known that betamethasone can raise blood sugar levels in women with diabetes, we want to find out if it does the same in non-diabetic women. The researchers will use continuous glucose monitoring to keep track of the participants' blood sugar levels during treatment.

To be eligible for this study, women must be pregnant between 24 to 34 weeks and experiencing signs of preterm birth, such as contractions or water breaking. They should also be over 18 years old and able to understand Danish. Women who have diabetes, are pregnant with more than one baby, or are taking certain medications that could affect blood sugar levels are not eligible. Participants can expect to receive betamethasone as part of their care, and researchers will monitor their blood sugar closely to gather important information about how this treatment impacts them.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:
• • Premature contractions and shortening of the cervix, or
• • Preterm premature rupture of membranes.
• • Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
• • Age over 18 years
• • Read and understand Danish
• Exclusion Criteria:
• • Multiple pregnancy
• • Diabetes
• • Pre-existing maternal use of medications that affect glucose metabolism